23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › CRINETICS PHARMACEUTICALS INC. › 2023-2024

CRINETICS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and CRINETICS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 246Asset managers, any item
  • 1,495Fund votes
  • June 7, 2024Meeting date

Results at a glance

Meeting of June 7, 2024: 4 items on CRINETICS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2024: 2 approved · 2 passed (calculated).

Dissent

Significant dissent: 2 directors (23.5%, 22.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CRINETICS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by CRINETICS PHARMACEUTICALS INC.

These tallies are CRINETICS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CRINETICS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 7, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Camille Bedrosian, M.D. 50,829,173---- 14,947,3212,328,910 77%Passed (calculated)—
Elect Director: Wendell Wierenga, Ph.D. 50,300,772---- 15,475,7222,328,910 76%Passed (calculated)—
2. Ratification of Selection of Independent Registered Accounting Firm 67,973,983115,42215,999 --0 99.8%Approved—
3. Approval, on an advisory basis, of the compensation of the Company's named executive officers 64,052,1271,745,5896,019 --2,301,669 97%Approved—

Source: CRINETICS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.

How asset managers voted at the CRINETICS PHARMACEUTICALS INC. 2023-2024 meeting

246 asset managers disclosed a vote on at least one CRINETICS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Camille Bedrosian, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD
FOR: 50,829,173WITHHELD: 14,947,321
Details: description as filed, official tally, votes by 86 asset managers

Description as filed by funds: To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Camille Bedrosian, M.D.

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Camille Bedrosian, M.D.”): 50,829,173 for, 14,947,321 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 24,727,122 for, 128 against, 4,324,565 withheld.

FORWITHHOLD
FOR: 24,727,122AGAINST: 128WITHHOLD: 4,324,565
Largest asset managers voting on “To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meet” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,530,1650 00For
T. Rowe Price4,733,7290 00For
Vanguard3,467,6220 00For
BlackRock2,356,2530 00For
Prudential/PGIM1,693,7620 0124,143Mixed
State Street1,757,9170 025,749For
MUTUAL FUND SERIES TRUST1,059,6330 00For
Bridge Builder Trust24,6590 0810,729Withhold
JANUS INVESTMENT FUND574,4220 0144,507Mixed
DRIEHAUS MUTUAL FUNDS00 0614,365Withhold
Lord Abbett00 0585,764Withhold
Charles Schwab481,4260 00For
Dimensional00 0450,780Withhold
TIAA440,2320 00For
Hartford403,0840 00For
Brinker Capital Destinations Trust2,2380 0269,041Withhold
JPMorgan248,7040 00For
John Hancock217,9640 024,073Mixed
Equitable192,3750 031,268Mixed
Victory Capital1,2400 0208,597Withhold
Goldman Sachs00 0173,991Withhold
First Trust00 0168,294Withhold
FRANKLIN STRATEGIC SERIES130,9220 00For
Invesco129,5690 00For
QUANTITATIVE MASTER SERIES LLC122,9570 00For

Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).

Elect Director: Wendell Wierenga, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD
FOR: 50,300,772WITHHELD: 15,475,722
Details: description as filed, official tally, votes by 86 asset managers

Description as filed by funds: To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Wendell Wierenga, Ph.D.

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Wendell Wierenga, Ph.D.”): 50,300,772 for, 15,475,722 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 24,462,565 for, 128 against, 4,589,122 withheld.

FORWITHHOLD
FOR: 24,462,565AGAINST: 128WITHHOLD: 4,589,122
Largest asset managers voting on “To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meet” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,530,1650 00For
T. Rowe Price4,733,7290 00For
Vanguard3,467,6220 00For
BlackRock2,356,2530 00For
Prudential/PGIM1,693,7620 0124,143Mixed
State Street1,757,9170 025,749For
MUTUAL FUND SERIES TRUST1,059,6330 00For
Bridge Builder Trust24,6590 0810,729Withhold
JANUS INVESTMENT FUND574,4220 0144,507Mixed
DRIEHAUS MUTUAL FUNDS00 0614,365Withhold
Lord Abbett00 0585,764Withhold
Charles Schwab481,4260 00For
Dimensional00 0450,780Withhold
TIAA440,2320 00For
Hartford403,0840 00For
Brinker Capital Destinations Trust2,2380 0269,041Withhold
JPMorgan248,7040 00For
John Hancock217,9640 024,073Mixed
Equitable126,1050 097,538Mixed
Victory Capital1,2400 0208,597Withhold
Goldman Sachs00 0173,991Withhold
First Trust00 0168,294Withhold
FRANKLIN STRATEGIC SERIES130,9220 00For
Invesco00 0129,569Withhold
QUANTITATIVE MASTER SERIES LLC122,9570 00For

Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).

Approval, on an advisory basis, of the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 16 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 64,052,127AGAINST: 1,745,589

Prior year: 97.4% for (June 16, 2023 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 246 asset managers

Description as filed by funds: To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 64,052,127 for, 1,745,589 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three - Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 85 asset managers voting on “To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,530,1650 00For
T. Rowe Price4,733,7290 00For
Vanguard3,467,6220 00For
BlackRock2,356,2530 00For
Prudential/PGIM1,796,48921,416 00For
State Street1,776,3897,277 00For
MUTUAL FUND SERIES TRUST1,059,6330 00For
Bridge Builder Trust811,98723,401 00For
JANUS INVESTMENT FUND718,9290 00For
DRIEHAUS MUTUAL FUNDS614,3650 00For
Lord Abbett585,7640 00For
Charles Schwab481,4260 00For
Dimensional450,7800 00For
TIAA440,2320 00For
Hartford403,0840 00For
Brinker Capital Destinations Trust271,2790 00For
JPMorgan248,7040 00For
John Hancock242,0370 00For
Equitable223,6430 00For
Victory Capital209,8370 00For
Goldman Sachs173,9910 00For
First Trust168,2940 00For
FRANKLIN STRATEGIC SERIES130,9220 00For
Invesco0129,569 00Against
QUANTITATIVE MASTER SERIES LLC122,9570 00For

Fund voting reports, all 85 managers: 28,800,903 for, 250,784 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 188 asset managers voting on “To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price6,419,6460 00For
Fidelity4,458,1830 00For
DRIEHAUS CAPITAL MANAGEMENT LLC3,820,4210 00For
State Street3,007,84527,291 00For
Point722,789,9340 00For
JENNISON ASSOCIATES LLC2,596,9685,054 00For
Wellington2,192,1570 00For
Paradigm Biocapital Advisors LP2,140,4580 00For
EcoR1 Capital, LLC2,012,5170 00For
BlackRock1,971,11912,267 00For
First Light Asset Management, LLC1,631,9380 00For
Janus Henderson1,610,5392,972 00For
GEODE CAPITAL MANAGEMENT, LLC1,400,8460 00For
ORBIMED ADVISORS LLC1,280,8000 00For
Cormorant Asset Management, LP1,217,6320 00For
Novo Holdings A/S1,098,6000 00For
PERCEPTIVE ADVISORS LLC1,000,0120 00For
Ensign Peak Advisors, Inc858,8280 00For
LORD, ABBETT & CO. LLC790,4030 00For
Laurion Capital Management LP598,1670 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.594,0370 00For
BNP Paribas Asset Management Holding S.A.0542,708 00Against
JPMorgan516,7730 00For
FRANKLIN ADVISERS INC516,4140 00For
Nuveen493,9470 00For

Institutional-manager reports, all 188 managers: 51,786,031 for, 1,492,954 against, 1,260 abstained, 800 not voted, 11 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of Independent Registered Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 67,973,983AGAINST: 115,422

Prior year: 100.0% for (June 16, 2023 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 86 asset managers

Description as filed by funds: To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Selection of Independent Registered Accounting Firm”): 67,973,983 for, 115,422 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Selection of Independent Registered Accounting Firm The Company's stockholders ratified the selection of BDO USA, P.C. as the Company's independent registered accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 29,048,580 for, 3,235 against.

FOR
FOR: 29,048,580AGAINST: 3,235
Largest asset managers voting on “To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered pub” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,530,1650 00For
T. Rowe Price4,733,7290 00For
Vanguard3,467,6220 00For
BlackRock2,356,2530 00For
Prudential/PGIM1,817,9050 00For
State Street1,780,6253,041 00For
MUTUAL FUND SERIES TRUST1,059,6330 00For
Bridge Builder Trust835,3880 00For
JANUS INVESTMENT FUND718,9290 00For
DRIEHAUS MUTUAL FUNDS614,3650 00For
Lord Abbett585,7640 00For
Charles Schwab481,4260 00For
Dimensional450,7800 00For
TIAA440,2320 00For
Hartford403,0840 00For
Brinker Capital Destinations Trust271,2790 00For
JPMorgan248,7040 00For
John Hancock242,0370 00For
Equitable223,6430 00For
Victory Capital209,8370 00For
Goldman Sachs173,9910 00For
First Trust168,2940 00For
FRANKLIN STRATEGIC SERIES130,9220 00For
Invesco129,5690 00For
QUANTITATIVE MASTER SERIES LLC122,9570 00For

Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).

Largest CRINETICS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 78,539,000 shares outstanding at the time of that meeting.

Fund voting reports: top CRINETICS PHARMACEUTICALS INC. shareholders by shares voted on “To consider and vote upon, on an advisory basis, the compensation of the Company's named…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 7.04%
2T. Rowe Price 6.03%
3Vanguard 4.42%
4BlackRock 3.00%
5Prudential/PGIM 2.31%
6State Street 2.27%
7MUTUAL FUND SERIES TRUST 1.35%
8Bridge Builder Trust 1.06%
9JANUS INVESTMENT FUND 0.92%
10DRIEHAUS MUTUAL FUNDS 0.78%
Institutional-manager reports: top CRINETICS PHARMACEUTICALS INC. shareholders by shares voted on “To consider and vote upon, on an advisory basis, the compensation of the Company's named…”, 2023-2024
#Asset manager % of shares outstanding
1T. Rowe Price 8.17%
2Fidelity 5.68%
3DRIEHAUS CAPITAL MANAGEMENT LLC 4.86%
4State Street 3.86%
5Point72 3.55%
6JENNISON ASSOCIATES LLC 3.31%
7Wellington 2.79%
8Paradigm Biocapital Advisors LP 2.73%
9EcoR1 Capital, LLC 2.56%
10BlackRock 2.53%

Reported CRINETICS PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

CRINETICS PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)14,187,498 18.06%Form 13F, quarter ended March 31, 2024
Vanguard Group9,170,129 11.68%Form 13F, quarter ended March 31, 2024
BlackRock7,586,597 9.66%Form 13F, quarter ended March 31, 2024
Point724,949,486 6.30%Form 13F, quarter ended March 31, 2024
T. Rowe Price3,823,218 4.87%Form 13F, quarter ended March 31, 2024
State Street3,255,253 4.14%Form 13F, quarter ended March 31, 2024
Wellington Management2,971,582 3.78%Form 13F, quarter ended March 31, 2024
Perceptive Advisors LLC1,488,703 1.90%Schedule 13D, filed March 1, 2024
Geode Capital1,401,403 1.78%Form 13F, quarter ended March 31, 2024
JPMorgan Chase1,258,722 1.60%Form 13F, quarter ended March 31, 2024

Percentages above are of 78,539,000 shares outstanding, as reported by CRINETICS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At CRINETICS PHARMACEUTICALS INC.'s shareholder meeting held June 7, 2024, in the 2023-2024 proxy season, 246 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,495 separate fund positions. On the most widely held item on that ballot — To consider and vote upon, on an advisory basis, the compensation of the Company's named… — CRINETICS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CRINETICS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CRINETICS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

CRINETICS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “CRINETICS PHARMACEUTICALS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/crinetics-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.